Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Biopharmx Corp (BPMX)

Biopharmx Corp (BPMX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,818
  • Shares Outstanding, K 14,187
  • Annual Sales, $ 60 K
  • Annual Income, $ -17,260 K
  • 60-Month Beta -0.32
  • Price/Sales 82.14
  • Price/Cash Flow N/A
  • Price/Book 2.12
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.35
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 12/05/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 10/31/19
See More
  • Average Estimate -0.11
  • Number of Estimates 1
  • High Estimate -0.11
  • Low Estimate -0.11
  • Prior Year -0.50
  • Growth Rate Est. (year over year) +78.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.30 +8.82%
on 09/30/19
0.41 -19.34%
on 10/18/19
-0.04 (-10.62%)
since 09/20/19
3-Month
0.30 +10.12%
on 08/07/19
0.49 -32.51%
on 07/23/19
-0.09 (-21.89%)
since 07/19/19
52-Week
0.30 +10.12%
on 08/07/19
4.75 -93.04%
on 11/13/18
-4.17 (-92.65%)
since 10/19/18

Most Recent Stories

More News
BioPharmX Receives Notice of Compliance Deadline Extension from NYSE American

BioPharmX Corporation (NYSE American: BPMX) (the "Company"), a specialty pharmaceutical company focused on developing innovative medical dermatology products, received a notice on September 19, 2019 from...

BPMX : 0.33 (-2.94%)
BioPharmX Reports Fiscal Second Quarter 2020 Financial Results and Provides Corporate Update

BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today reports financial results for the fiscal quarter ended...

BPMX : 0.33 (-2.94%)
BioPharmX Announces Steven M. Bosacki Joins the Company as Chief Operating Officer

BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today announces the appointment of Steven M. Bosacki, a 20...

BPMX : 0.33 (-2.94%)
Thinking about buying stock in Allergan, Biopharmx, Beyond Meat, Immunic, or Riot Blockchain?

InvestorsObserver issues critical PriceWatch Alerts for AGN, BPMX, BYND, IMUX, and RIOT.

AGN : 174.01 (+0.24%)
BPMX : 0.33 (-2.94%)
RIOT : 1.70 (-0.58%)
BioPharmX Announces Positive Topline Results from Phase 2b Trial of BPX-04 for Papulopustular Rosacea

BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today announced positive results from its Phase 2b clinical...

BPMX : 0.33 (-2.94%)
BioPharmX Announces Reverse Stock Split

BioPharmX Corporation (NYSE American: BPMX) (the "Company"), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today announced that its Board of Directors...

BPMX : 0.33 (-2.94%)
Research Report Identifies TTM Technologies, Zumiez, Global Net Lease, Catabasis Pharmaceuticals, BioPharmX, and Protalix BioTherapeutics with Renewed Outlook -- Fundamental Analysis, Calculating Forward Movement

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of TTM Technologies, Inc. (NASDAQ:TTMI),...

TTMI : 12.58 (+2.95%)
ZUMZ : 33.12 (+1.41%)
GNL : 19.40 (+0.15%)
CATB : 4.62 (-1.07%)
BPMX : 0.33 (-2.94%)
PLX : 0.28 (-3.45%)
BioPharmX Announces $3.9 Million Offering

BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today announced that it has entered into securities purchase...

BPMX : 0.33 (-2.94%)
BioPharmX to Participate in the 31st Annual ROTH Conference and the Oppenheimer 29th Annual Healthcare Conference

BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today announced presentations at multiple upcoming investor...

BPMX : 0.33 (-2.94%)
BioPharmX Reports Fourth Quarter and Full Year 2019 Financial Results

BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today reports financial results for the quarter and year ended...

BPMX : 0.33 (-2.94%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade BPMX with:

Business Summary

BioPharmX Corporation is a specialty pharmaceutical company. The company focuses on the development of novel drug delivery products for women's health, dermatology and otolaryngology markets. The Company's product pipeline includes products in categories consists of prescription products, over-the-counter...

See More

Key Turning Points

2nd Resistance Point 0.44
1st Resistance Point 0.39
Last Price 0.33
1st Support Level 0.31
2nd Support Level 0.28

See More

52-Week High 4.75
Fibonacci 61.8% 3.05
Fibonacci 50% 2.53
Fibonacci 38.2% 2.00
Last Price 0.33
52-Week Low 0.30

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar